Company news

NeoGenomics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

NeoGenomics Reports First Quarter 2023 Results

May 7, 2023

NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference

May 2, 2023

NeoGenomics to Announce First Quarter 2023 Financial Results

April 16, 2023

NeoGenomics to Participate at the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023

NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023

April 5, 2023

NeoGenomics to Host Investor Day on April 4, 2023

March 26, 2023

Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care

March 21, 2023

NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test

March 15, 2023

NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP

March 12, 2023

NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference

February 27, 2023

NeoGenomics Reports Fourth Quarter and Full Year 2022 Results

February 22, 2023

RaDaR(R) Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery

February 5, 2023

NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023

February 5, 2023

NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 4, 2022

NeoGenomics Announces Chief Financial Officer Transition

December 4, 2022

RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

November 20, 2022

NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)

November 17, 2022

NeoGenomics Reports Third Quarter 2022 Results

November 7, 2022

NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors

November 6, 2022

NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch

October 27, 2022

NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022

October 12, 2022

NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022

September 6, 2022

NeoGenomics Reports Revenue of $125 Million in the Second Quarter

August 8, 2022

NeoGenomics Announces Chief Executive Officer Appointment

July 20, 2022

NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022

July 14, 2022

NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer

June 20, 2022

NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences

June 2, 2022

NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory

June 2, 2022

NeoGenomics Appoints Lynn Tetrault Interim CEO

May 15, 2022

NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting

May 9, 2022

NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary

May 8, 2022

NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference

May 4, 2022

NeoGenomics Reports Revenue of $117 Million in the First Quarter

April 26, 2022

NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay

April 24, 2022

NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D

April 10, 2022

NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay MRD Assay at AACR 2022

April 10, 2022

NeoGenomics Schedules its First Quarter 2022 Earnings Release for April 27, 2022

April 7, 2022

NeoGenomics Announces CEO Departure and Initiates CEO Search

March 27, 2022

NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay in Non-Small Cell Lung Cancer

March 16, 2022

NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021

February 22, 2022

NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific Officer

February 13, 2022

NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma

February 10, 2022

NeoGenomics to Participate Virtually in Multiple Upcoming Institutional Investor Conferences

February 7, 2022

NeoGenomics Schedules its Fourth Quarter and Full Year 2021 Earnings Release for February 23, 2022

February 1, 2022

NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results

January 23, 2022

NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program

January 10, 2022

NeoGenomics Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid Biopsy Subsidiary

December 12, 2021

NeoGenomics to Leverage Thermo Fisher Scientific’s Ion Torrent Genexus System in Upcoming Phase 1 Study for Myeloid Cancers

December 9, 2021

NeoGenomics To Participate In The Stephens Annual Investment Conference 2021

November 29, 2021

NeoGenomics Appoints Dave Daly to Its Board of Directors

November 9, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 40 decks. Every deck is listed under its year.